HR-7653-119
Ordered to be Reported by the Yeas and Nays: 46 - 0.
Sponsored by Keith Self (R-TX)
What it does
This bill would direct the Secretary of State to pursue enhanced cooperation with NATO allies and other U.S. partner countries on biodefense, biosecurity, and biotechnology matters. It would require the State Department to develop two formal strategies — a NATO Biodefense Strategy and an International Biotechnology, Biosecurity, and Biodefense Cooperation Strategy — and submit them to Congress within 270 days. The bill would also require a congressional briefing within 90 days on significant global biotechnology and biosecurity developments.
Who benefits
U.S. national security and defense agencies that would gain a clearer diplomatic framework for biodefense coordination. NATO member states and major non-NATO allies that would benefit from stronger collective biosecurity standards. U.S. biotechnology companies that could benefit from harmonized international export control policies. Public health institutions and researchers who would benefit from improved international biosurveillance networks. Communities that could be better protected from biological threats through improved international early-warning systems.
Who is hurt
U.S. biotechnology and life sciences companies whose dual-use research or exports could face new or expanded restrictions under coordinated export control policies. Academic and research institutions engaged in international biological research collaborations that may face additional compliance burdens. State Department staff who would bear the workload of developing two new strategies and delivering congressional briefings within tight deadlines. Countries not designated as U.S. allies or major non-NATO allies that could be excluded from cooperative frameworks, potentially widening global biosecurity gaps.
Supporters argue
Supporters argue that biological threats — whether from state actors, non-state groups, or natural outbreaks — are among the most serious and underaddressed national security risks, as demonstrated by the COVID-19 pandemic and ongoing concerns about state-sponsored bioweapons programs. They contend that the U.S. currently lacks a coherent diplomatic strategy for biodefense within NATO, and that this bill fills that gap by requiring concrete planning, gap assessments, and allied coordination — all without mandating new spending or binding commitments. The bill's bipartisan sponsorship and unanimous 46-0 committee vote suggest broad agreement that stronger international biodefense diplomacy is overdue.
Opponents argue
Opponents argue that the bill creates new bureaucratic reporting mandates without providing dedicated funding or enforcement mechanisms, raising questions about whether the resulting strategies will be substantive or merely procedural exercises. They contend that existing frameworks — including the Biological Weapons Convention, the Australia Group, and NATO's existing CBRN Defence Policy — already address many of the bill's goals, and that duplicating these efforts could create coordination confusion rather than clarity. Critics may also argue that tightening biotechnology export controls risks disadvantaging U.S. companies in global markets and chilling legitimate international scientific collaboration.